
Publication
Strategic asset search and evaluation in biopharma
Biotechnology companies are primarily built around platform technologies and focused on asset specific value creation.
Private equity sponsors have enjoyed a strong deal environment during a period of sustained economic growth. But PE firms are now facing significant challenges. Sponsors remain under tremendous pressure to deploy capital against continuing high multiples and resulting high enterprise values. Amidst a continuing proliferation of investment dollars competing for fewer good deals, the PE industry and its portfolio companies must deal with rising inflation within a generally uncertain economy, increasing geopolitical tensions, renewed regulatory gauntlets, and swelling social impact pressures. Successful transactions will require that PE sponsors become nimble, move quickly, and readjust strategies.
Read the full Bloomberg Law article, "Private equity challenges necessitate reevaluating strategies."
Publication
Biotechnology companies are primarily built around platform technologies and focused on asset specific value creation.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright US LLP 2025